Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study
- 1 November 2020
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 46, 102438
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
This publication has 16 references indexed in Scilit:
- Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Neurology, 2014
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Neurology, 2014
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialMultiple Sclerosis Journal, 2013
- Facilitating Medication Adherence in Patients with Multiple SclerosisInternational Journal of MS Care, 2013
- Teriflunomide added to interferon-β in relapsing multiple sclerosisNeurology, 2012
- Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 yearsMultiple Sclerosis Journal, 2012
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple SclerosisNew England Journal of Medicine, 2011
- Medication Adherence: WHO Cares?Mayo Clinic Proceedings, 2011
- A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesNeurology, 2006
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Annals of Neurology, 2005